Drug interactions in oncology: how common are they?

Riechelmann, Rachel P.; Giglio, Auro del

doi:10.1093/annonc/mdp369

Cited by 141 publications

(114 citation statements)

References 29 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…For instance, one U.S. study of css found that 96% consumed at least 1 prescription drug, and 71%, at least 1 otc drug, 3 days before their chemotherapy 23 . Another analysis observed that 2% of unplanned hospital visits by css were secondary to drug interactions 24 . That finding likely underestimates the true frequency, because concomitant complaints and symptoms at the time of medical presentation might lead clinicians to attribute a hospital visit to a cause other than drug interaction.…”

Section: Discussionmentioning

confidence: 99%

Potential Drug Interactions in Patients with a History of Cancer

Chen

Cheung

2014

Current Oncology

View full text Add to dashboard Cite

Background: Cancer survivors (css) are frequently exposed to polypharmacy, which might increase their risk of drug interactions. Our study aimed to determine the relative prevalence of potential drug interactions (pdis) among css compared with non-cancer respondents (ncrs). Methods: Self-reported prescription data from 4975 patients were extracted from the U.S. National Health and Nutrition Examination Survey and screened for pdis using iFacts: Drug Interaction Facts (Facts and Comparisons, St. Louis, MO, U.S.A.). The clinical significance of each pdi was graded on a 5-point scale based on the severity of the interaction and the level of evidence documenting the interaction. Summary statistics and logistic regression models were used to assess the impact of cancer history on the risk of pdis. Results: Of patients eligible for the analyses, the css (n = 302) indicated using 4.4 ± 0.22 prescriptions on average, and the ncrs (n = 908), 3.8 ± 0.09. Nearly half of both cohorts (40% of css, 43% of ncrs) had at least 1 pdi. In both cohorts, 12% were at risk for fatal or permanently debilitating effects. In multivariate analyses, css were significantly less likely than ncrs to be at risk for any pdis (odds ratio: 0.65; 95% confidence interval: 0.46 to 0.92; p = 0.02). Advanced age and low household income were associated with pdis among css. Medications most commonly prescribed to css with a pdi included metoprolol (15.6%), levothyroxine (13.6%), and furosemide (11.9%). Conclusions: Although css appear to be less susceptible than ncrs to pdis, the prevalence of pdis among css remains suboptimal. Specific subgroups of css may be particularly prone to pdis, underscoring the importance of increased vigilance.

show abstract

Section: Discussionmentioning

confidence: 99%

Potential Drug Interactions in Patients with a History of Cancer

Chen

Cheung

2014

Current Oncology

View full text Add to dashboard Cite

show abstract

“…The observation that patients in the oncology setting are at a higher potential risk for drug-drug interactions (DDIs) has been covered extensively (Beijnen and Schellens, 2004;Blower et al, 2005;Meijerman et al, 2006;Scripture and Figg, 2006;Hanigan, 2009;Riechelmann and Del Giglio, 2009). Cancer patients often require additional medications because of treatment-induced toxicity and cancer-related syndromes (Riechelmann and Del Giglio, 2009).…”

Section: Discussionmentioning

confidence: 99%

In Vitro Characterization of the Drug-Drug Interaction Potential of Catabolites of Antibody-Maytansinoid Conjugates

et al. 2012

View full text Add to dashboard Cite

ABSTRACT:The in vitro characterization of the inhibition potential of four representative maytansinoid species observed upon hepatic and/or tumor in vivo processing of antibody-maytansine conjugates (AMCs) with cleavable and noncleavable linkers is reported. We investigated the free maytansinoid species , respectively. Because of instability in plasma, further characterization of the DM1 and DM4 intramolecular and intermolecular disulfide conjugates observed in vivo is required before an accurate drug-drug interaction (DDI) prediction can be made. AMCs with noncleavable thioether-linked DM1 as the cytotoxic agent are predicted to have no potential for a DDI with any of the major human P450s studied.

show abstract

“…Approximately 20% to 30% of all adverse events (AEs) are caused by interactions between drug. 18,19 We observed inappropriate drug chart recorded in about 1% (08) of the participants, while Itchipruchyabun A et al showed incomplete patient's data in 21 cases (30.88%). 15 These findings indicate as presence of patient chart registration or unclear order before starting a chemotherapy problem and it may affect therapeutic outcome.…”

Section: Discussionmentioning

confidence: 78%

Exploring troublesome symptom and problems experienced by cancer patients undergoing chemotherapy

Singh¹,

Singh²,

Singh³

et al. 2016

JYP

View full text Add to dashboard Cite

Objective: The objective of this cross-sectional, non interventional 8-months observational study was to investigate the prevalence, type and risk factors of Drug related problem (DRPs) in cancer patients admitted to the Oncology Department of Guru Gobind Singh Medical College, Faridkot, Punjab. Methods: A cross-sectional 8 months study was conducted from January to August 2015 at the Oncology Department of Guru Gobind Singh Medical College, Faridkot, Punjab. A total of 283 cancer patients were recruited in the present investigation analysis. Results: A total of 283 cancer patients participated in this current study, out of which 135 (47.70%) were males and 148 (52.30%) were females. Adverse drug reactions (ADRs) were the most common DRP, nausea and vomiting was the most common ADR (155). Female subjects experienced more DRPs 56% as compare to 44% in male cancer survivors. Conclusion: This study showed that DRPs were common in our setup and the risk factors associated with DRPs were female gender, number of medications, Body mass index and extremes age (in year) ranges. Early detection and timely intervention is the key to ensure a better therapeutic outcome.

show abstract

Drug interactions in oncology: how common are they?

Abstract: Drug interactions comprise an important issue in oncology, with approximately one-third of ambulatory cancer patients being at risk of DDIs. Data are limited on the clinical consequences of drug interactions among cancer patients.

Cited by 141 publications

References 29 publications

Potential Drug Interactions in Patients with a History of Cancer

Potential Drug Interactions in Patients with a History of Cancer

In Vitro Characterization of the Drug-Drug Interaction Potential of Catabolites of Antibody-Maytansinoid Conjugates

Exploring troublesome symptom and problems experienced by cancer patients undergoing chemotherapy

Contact Info

Product

Resources

About